Home/Blog/Do Stocks Go Up After FDA Approval? What Data Shows
BLOG

Do Stocks Go Up After FDA Approval? What Data Shows

By , founder · Published · 9 min read

Key takeaways

  • Biotech stocks tend to rise on approvals over large samples, but much of the move happens in the pre-PDUFA run-up, so approval-day pops are smaller than expected and often fade.
  • A complete response letter gaps harder and faster than an approval pops, because it deletes the priced-in approval scenario entirely and the catalyst is not rescheduled.
  • The PDUFA date is the FDA's internal goal date, not an announcement time: decisions land early or slip, so treat it as the center of a window and monitor for the letter itself.
  • Approval type changes the trade: NDA and BLA decisions are binary full-cap repricing events, while sNDA/sBLA label expansions move incrementally on label breadth.
  • The tradable edge is the gap between what was priced in and what the decision letter actually says, which makes sub-minute alerts on the primary FDA source more valuable than headline confirmations.

Not reliably. Stocks tend to rise on approvals over large samples, but the trade is messier: biotechs often run up into the PDUFA date, then sell off on the actual approval news as the catalyst gets priced in. The outcome depends on the approval type, the decision timing, and whether the move was front-run.

Do Biotech Stocks Rise on Approval Day, on Average?

On average, yes — but the move is front-loaded and often partially reverses. Event studies of biotech approval decisions consistently show the run-up happens before the PDUFA date as traders position early, so approval-day pops are smaller than expected and frequently fade within days. Approval is not automatically a buy event; it is a catalyst with a known shape.

The mechanics matter. An FDA decision is a formal action on a marketing application, not a single announcement moment, and the agency publishes the decision types (NDA, BLA, supplemental) that drive different trade behavior (FDA, Development & Approval Process).

If you trade the initial move, your edge comes from knowing which part of the curve you're entering: pre-decision positioning, the decision letter itself, or the post-approval fade. We cover the stock-side basics in how to start trading stocks, but futures traders reading this should treat FDA events as timing problems first.

What the Historical Data Shows Around Approval Events

The pre-approval run-up

The move usually starts before the PDUFA date. Traders position ahead of the catalyst, so much of the approval-day gain is already gone by the time the letter hits.

The approval-day move

The average approval-day pop is smaller than most traders expect, and it varies wildly by decision type and how contested the drug's efficacy data was. A clean approval on a widely expected outcome often barely moves the stock; a surprise or a surprising label detail moves it hard.

The post-approval sell-off

The "sell the news" pattern is real: stocks that ran hard into a decision frequently fade once the catalyst resolves, regardless of the outcome.

The reason is simple: an approval is a known event on a known date, so the market prices the expected result in advance. What's left to trade is the surprise component, the gap between what was expected and what the FDA letter actually says. That's the same mechanism behind how CPI moves stocks: consensus is priced, the release itself is noise, and the initial move belongs to whoever reads the primary source first. If you're waiting for the headline to confirm the approval, you're buying into the fade, not the move.

Approval vs Rejection: How the Downside Differs

Complete response letters

When the FDA issues a complete response letter (CRL) instead of approval, the company must address deficiencies, run additional trials, or supply more data before resubmission. There is no new PDUFA date until the sponsor refiles, so the catalyst doesn't get rescheduled, it evaporates. The FDA outlines this review structure, including goal dates and CRLs, on its PDUFA and review process page.

Why rejections gap harder than approvals pop

Approvals are partially priced in during the run-up, so the pop is the marginal surprise. A CRL is a full repricing: the market deletes the approval scenario entirely, and longs who bought the run-up sell into a bid that has already pulled. That asymmetry means the rejection move is faster, not just bigger. The same logic applies to any scheduled catalyst where consensus leans one way; we cover the mechanics in how to trade FOMC meetings.

NDA vs BLA vs Supplemental: Why the Approval Type Changes the Trade

The approval pathway tells you what kind of catalyst you're trading: a first-launch event, a first-biologic event, or an incremental label expansion. The market treats these very differently.

NDA: new small-molecule drug

An NDA approval is the first time the drug can be sold, so the decision reprices the entire company. Pre-PDUFA run-ups are common, and the post-announcement move depends on the label: a broad indication with clean safety language supports the move, a boxed warning or narrow population can fade it.

BLA: biologic, first approval

A BLA is structurally similar to an NDA but carries manufacturing scrutiny (facility review can delay or complicate the decision). First biologic approvals often trade like NDAs: binary, full-cap repricing events.

sNDA/sBLA: supplemental and label expansion

Supplementals add indications to an already-approved drug. The market impact is smaller because the drug is already on the market and revenue base is known. These trade more on label breadth and addressable population than on survival of the company.

PathwayFirst approval?Typical market impact
NDAYes, new drugFull repricing, binary
BLAYes, first biologicFull repricing, binary
sNDA/sBLANo, label expansionIncremental, magnitude-based

Whatever the pathway, the trade lives or dies on latency. A decision letter hits the wire before it hits your feed, and the first minutes carry the move. Tradar is built for exactly that window: real-time alerts on FDA decisions with an impact score so you can trade the catalyst, not the noise (see how we cover scheduled catalysts).

PDUFA Date vs Actual Decision: Timing the Catalyst

What a PDUFA date actually is

The PDUFA date is FDA's internal goal date for finishing its review, not a scheduled announcement. It's a deadline for the agency's decision workflow, set under the review timelines governed by the NDA and BLA pathways. The FDA can issue an action letter any time before that goal date, and nothing requires the letter to arrive on the date itself.

Early decisions and goal-date extensions

Decisions regularly land days or weeks early, especially when the review is straightforward. On the other side, the FDA can extend the goal date to review additional data, which pushes the catalyst out with no public countdown. Traders positioning for a specific date get caught flat when the letter arrives Tuesday instead of Friday, or when the date silently slips a month.

Trading the window, not the date

Treat the PDUFA date as the center of a window, not an event time. That means monitoring the ticker for the actual decision letter rather than calendar reminders, since the first move happens when the letter posts, not when the goal date hits. The same logic applies to any scheduled catalyst: SBUX earnings moved the moment the release hit, not at the scheduled minute, which is why we break down that print in our SBUX news alert walkthrough.

Why Approval Is Often 'Priced In' Before the Announcement

Probability already embedded in the price

By the time a PDUFA date is weeks away, the market has already assigned a probability to approval. Advisory committee votes, trial data readouts, and even FDA feedback letters get traded months in advance, so a stock can run 50-100% before the decision letter ever lands. If you're buying the headline, you're buying at the price that already reflects the most likely outcome.

Sell-the-news dynamics

A clean approval can still sell off hard because the buyers who built the run-up were positioning for the event, not the drug. Once the binary resolves, they take profit into the liquidity of the news spike. That's why the first move after approval is frequently down, especially when the run-up was steep or the label came back narrower than hoped.

The tradable edge isn't the approval itself. It's the gap between what was priced in and what the decision letter actually says — label scope, trial size, post-marketing requirements. That's why sub-minute delivery of the actual FDA text matters more than a push notification saying "approved."

How to Trade an FDA Decision: A Practical Framework

Map the scenarios before the window opens

Write down three outcomes before the PDUFA window: approval, complete response letter, and deferral. A CRL is not a flat rejection; the FDA issues one when it wants more work, and the stock reaction depends on what the letter asks for. Read the FDA's own description of the complete response process so your downside scenario matches what a CRL actually means.

Size for a gap risk you cannot exit

Assume you will not get a fill on the first print after the decision. Size so a 40 to 60 percent adverse gap is survivable, not so a 10 percent stop is tolerable. If you are holding through the announcement, that position is a bet on the event, not a trade on the move.

Where real-time alerts fit

The decision letter hits the wire minutes before the stock moves. A sub-minute alert on the primary source is the difference between trading the initial move and reading about it on FinTwit five minutes later.

Which Tools Get You the Decision First

For speed on FDA decisions, the free options break down fast. CNBC: Stock Market & Business and Yahoo Finance: Stocks, Markets push headlines within minutes, not seconds, and Bloomberg: Business News Daily sits behind a subscription wall for anything real-time. Seeking Alpha: News & Analysis adds context but arrives after the first move. Stocks News: Market Headlines aggregates wire copy quickly, though wire copy alone rarely tells you it was an approval letter versus a CRL.

Tradar is built for this exact moment: push alerts on FDA catalysts aimed at landing on your screen before the move is fully priced in, with the primary source linked so you can verify in seconds. Where it falls short: it's a mobile alert product, not a terminal. You get the catalyst and the source, not deep pipeline analytics or sell-side models. If you want analysis, pair it with Seeking Alpha. If you want the decision first, the alert has to come from something watching FDA.gov directly.

FAQ

How much do biotech stocks typically move on FDA approval day?

Approval-day pops are usually smaller than traders expect because much of the move happens during the pre-PDUFA run-up. A clean approval on a widely anticipated outcome can barely move the stock, while a surprise decision or unexpected label detail can produce a large gap. Magnitude varies heavily by decision type and how contested the efficacy data was.

Do stocks go up after FDA approval if the drug was already expected to be approved?

Often no. When the market has already priced a high approval probability, the announcement carries little surprise, and stocks that ran hard into the decision frequently fade afterward regardless of outcome. The tradable move comes from the gap between expectations and what the letter actually says, such as label breadth or safety language, not from the approval headline.

Can the FDA approve a drug before the PDUFA date?

Yes. The PDUFA date is the agency's internal goal date for finishing its review, not a scheduled announcement. Decision letters regularly land days or weeks early, especially on straightforward reviews, and the FDA can also extend the goal date to review additional data. Treat the date as the center of a window and monitor for the letter itself.

What is a CRL and how bad is it for the stock?

A complete response letter means the FDA wants more work, such as additional trials, more data, or fixes to deficiencies, before it will approve. It is worse than a flat rejection for traders: approvals are partially priced in, but a CRL deletes the approval scenario entirely, so the stock gaps harder and faster, and the catalyst does not get rescheduled.

Is it too late to trade a biotech stock after the approval headline hits?

Usually yes for the initial move. The decision letter hits the wire before most feeds, and the first minutes carry the trade. By the time a headline confirms the approval, you are often buying into the post-announcement fade rather than the move. Sub-minute alerts on the primary source are what make trading the catalyst realistic.

Get the catalyst before it's priced in

Real-time alerts from 190+ active sources — SEC, FDA, the Fed — scored for impact and pushed to your phone.

Get Alerts